High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study

INTRODUCTION: The choice of therapy in patients withdrawing from natalizumab treatment is still an open question and neurologists need strategies to manage this group of patients. The aim of this study is to evaluate if alemtuzumab is able to control the disease when used in patient who have stopped...

Descripción completa

Detalles Bibliográficos
Autores principales: Malucchi, Simona, Capobianco, Marco, Lo Re, Marianna, Malentacchi, Maria, di Sapio, Alessia, Matta, Manuela, Sperli, Francesca, Bertolotto, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447551/
https://www.ncbi.nlm.nih.gov/pubmed/27915429
http://dx.doi.org/10.1007/s40120-016-0058-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447551/
https://www.ncbi.nlm.nih.gov/pubmed/27915429
http://dx.doi.org/10.1007/s40120-016-0058-0

Ejemplares similares